Monday, Biodel Inc. (BIOD) announced that the FDA has accepted the company's new drug application seeking approval to market VIAject for the treatment of diabetes.
VIAject, Biodel's lead product candidate is a rapid-acting form of injectable human insulin for meal-time use by patients with Type 1 or Type 2 diabetes. RTTNews had alerted readers to the stock on February 11 when the stock was trading at $3.65.
The company said that VIAject has been tested in more than 875 patients who participated in phase I, II and III clinical trials of the drug in the United States, Germany and India. Biodel submitted its marketing application to the regulatory agency on December 30, 2009 and expects the action date to be October 30, 2010.
BIOD, which has been trading in the range of $3.22-$6.02 over the past twelve months, rose as much as 14% to $4.55 in early trading, before settling down to the current trading price of $4.33.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.